Biotech companies at FoG London 2027

Jan 27–28, 2027 London, UK ~8.3k attendees Website

11 biotech companies are at FoG London 2027 — 12 presentations on the program. Most represented: Relation Therapeutics (5 on the program), Astex Pharmaceuticals (1 on the program), Axovia Therapeutics (1 on the program). 1 of them have their own page in this guide. As of Oct 29, 2026.

All 243 organizations at FoG London 2027 →

Topic
Top represented
Showing 1–11 of 11 organizations
OrganizationFoG London 2027 Attendance
Biotech
Drug discovery company combining single-cell and functional genomics data from patient tissue with machine learning to find drug targets.
Talk
Wed Jan 27
11:30–12:00
Relation's AI & Deep Learning Platform: What datasets the ML models are trained on
What biological and genomic datasets train deep learning models for drug discovery, and how data quality and diversity shape their performance.
Talk
Wed Jan 27
12:30–13:00
Spatial Total RNA Profiling via in situ Polyadenylation
How a new method maps all of each cell's RNA in tissue, revealing splicing and non-coding RNA even in wax-preserved clinical samples.
Panel
Wed Jan 27
17:30–18:00
Choosing the Right Sequencing Technology: Short Reads, Long Reads & Beyond
How researchers weigh short-read and long-read sequencing on accuracy, resolution, throughput and cost, and when to combine them.
with Wellcome Sanger Institute, AstraZeneca
Also
Presenting at the meeting, beyond the sessions above
Biotech
Drug discovery and development company, part of Otsuka, known for fragment-based small-molecule medicines in oncology.
Panel
Thu Jan 28
11:30–12:00
Are We Seeing Real Breakthroughs from AI, or Just Faster Trial and Error?
Whether AI-discovered drugs now reaching mid-stage trials are truly better molecules, and how success for AI in drug discovery should be measured.
with GSK, UCB, Ipsen +1 more
Biotech
Develops AAV gene therapies for ciliopathies, starting with BBS1-linked Bardet-Biedl syndrome, aiming to prevent blindness and treat genetic obesity.
Panel
Wed Jan 27
17:30–18:00
How Can We Bridge the Gap from Discovery to GMP Manufacturing?
When and how cell and gene therapy developers should plan manufacturing and regulation so a lab process can scale without losing quality.
with Resolution Therapeutics, Bayer, TTP
DP
DISCO Pharmaceuticals
Cologne, Germany
Biotech
Drug discovery company mapping cancer cell-surface proteins to find targets for antibody-based and other targeted therapies.
Panel
Wed Jan 27
17:30–18:00
Using High Dimensional Multi-Omic Data in Drug Discovery & Translational Research
How combining several layers of molecular data can reveal drug targets and biomarkers, and what slows their path to the clinic.
with Imperial College London, GSK
EB
Entelo Bio
Oxford, UK
Biotech
University of Oxford spinout using isoform-aware machine learning and multi-omics to discover drug targets, focused on movement and ageing disorders.
Panel
Thu Jan 28
11:30–12:00
Are We Seeing Real Breakthroughs from AI, or Just Faster Trial and Error?
Whether AI-discovered drugs now reaching mid-stage trials are truly better molecules, and how success for AI in drug discovery should be measured.
with GSK, UCB, Ipsen +1 more
Immunocore
Abingdon, UK
Biotech
Develops T cell receptor-based bispecific immunotherapies for cancer, infectious and autoimmune diseases, including the first approved TCR therapy.
Talk
Wed Jan 27
15:30–16:00
Engineering the Next Generation of Immunotherapies: Lessons from the First Approved T Cell Receptor-Based Therapy
Lessons from building the first approved T cell receptor-based therapy, and how its platform is now being extended to new molecules.
Biotech
Company using an AI design engine to engineer AAV gene therapy vectors with better tissue targeting and lower doses.
Panel
Wed Jan 27
12:30–13:00
Designing the Next Generation of Rare Disease Therapies: From Advanced Genomics to AI-Enabled Therapeutic Innovation
How better knowledge of disease genetics and AI could shape the design of more precise, personalised treatments for rare diseases.
with ABPI, Alexion, AstraZeneca Rare Disease, MeiraGTx
MeiraGTx
New York, NY
Biotech
Clinical-stage genetic medicine company developing gene therapies and riboswitch gene-regulation technology, with manufacturing in London.
Panel
Wed Jan 27
12:30–13:00
Designing the Next Generation of Rare Disease Therapies: From Advanced Genomics to AI-Enabled Therapeutic Innovation
How better knowledge of disease genetics and AI could shape the design of more precise, personalised treatments for rare diseases.
with ABPI, Alexion, AstraZeneca Rare Disease, Lir Therapeutics
Biotech
Flagship Pioneering company studying somatic mutations in healthy and diseased tissue to discover drug targets.
Talk
Thu Jan 28
12:30–13:00
Drug Target Discovery through Somatic Genomics
How somatic mutations, changes acquired in body cells, reveal disease-driving and protective biology that can point to new drug targets.
Biotech
Clinical-stage company developing engineered macrophage cell therapies to repair organ damage, starting with liver cirrhosis.
Panel
Wed Jan 27
17:30–18:00
How Can We Bridge the Gap from Discovery to GMP Manufacturing?
When and how cell and gene therapy developers should plan manufacturing and regulation so a lab process can scale without losing quality.
with Bayer, Axovia Therapeutics, TTP
Biotech
Drug discovery company using human extracellular matrix models to find treatments for fibrosis, inflammation and solid tumours.
Also
Presenting at the meeting, on no published session yet

Explore the full FoG London 2027 dataset

Get in-depth attendee and institution profiles and research, to plan your meetings in London. Leave your work email and we’ll be in touch.

Privacy

Download the full FoG London 2027 CSV

Leave your work email and we’ll be in touch. The CSV adds attendee names, roles and contact details to the company and session data shown here.

Privacy

Find buyers from biotech companies

Tell us what you sell and we’ll find the people at these biotech companies most likely to buy it.

  • Who to contact
  • Their contact info
  • What to say
  • Free, no sign-up

Browse FoG London 2027 by

Exhibit hall

Not affiliated with or endorsed by Front Line Genomics or the Festival of Genomics. Submit a correction